See more : AERWINS Technologies Inc. (AWIN) Income Statement Analysis – Financial Results
Complete financial analysis of Telix Pharmaceuticals Limited (TLPPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Telix Pharmaceuticals Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Prime Number Acquisition I Corp. (PNACU) Income Statement Analysis – Financial Results
- Wind Works Power Corp. (WWPW) Income Statement Analysis – Financial Results
- Alkem Laboratories Limited (ALKEM.BO) Income Statement Analysis – Financial Results
- Multitude SE (FRU.DE) Income Statement Analysis – Financial Results
- Kering SA (PPX.DE) Income Statement Analysis – Financial Results
Telix Pharmaceuticals Limited (TLPPF)
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 496.66M | 160.10M | 7.60M | 5.21M | 3.49M | 195.14K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 188.16M | 130.76M | 37.36M | 22.09M | 15.36M | 0.00 | 3.79K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 308.50M | 29.34M | -29.77M | -16.88M | -11.88M | 195.14K | -3.79K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 62.12% | 18.32% | -391.85% | -323.75% | -340.75% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 128.84M | 57.86M | 34.14M | 23.09M | 21.16M | 18.69M | 2.98M | 10.00K | 62.00K | 0.00 | 0.00 |
| General & Administrative | 78.99M | 77.32M | 34.92M | 7.71M | 6.51M | 8.50M | 2.46M | 20.00K | 54.00K | 0.00 | 0.00 |
| Selling & Marketing | 54.87M | 16.19M | 5.89M | 1.20M | 312.00K | 577.95K | 213.77K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 133.85M | 44.66M | 17.35M | 9.29M | 7.22M | 9.08M | 2.67M | 20.00K | 54.00K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 3.09M | 23.55M | 2.96M | 11.44M | 11.63M | 112.64K | 0.00 | 0.00 | -994.00K | -578.00K |
| Operating Expenses | 308.50M | 102.52M | 51.48M | 32.38M | 28.38M | 27.85M | 6.52M | 30.00K | 116.00K | -994.00K | -578.00K |
| Cost & Expenses | 451.03M | 233.28M | 88.84M | 54.47M | 43.74M | 27.85M | 6.52M | 30.00K | 116.00K | -994.00K | -578.00K |
| Interest Income | 235.00K | 1.00K | 163.00K | 67.00K | 98.00K | 332.75K | 38.98K | 14.00K | 16.00K | 0.00 | 0.00 |
| Interest Expense | 13.14M | 406.00K | 189.00K | 1.18M | 2.41M | 29.02K | 9.40K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.74M | 5.38M | 5.17M | 4.88M | 4.24M | 6.93K | 3.79K | 30.00K | 116.00K | 0.00 | 0.00 |
| EBITDA | 22.97M | -92.84M | -70.07M | -44.94M | -36.17M | -25.82M | -6.77M | -14.00K | -16.00K | -994.00K | -578.00K |
| EBITDA Ratio | 4.62% | -42.35% | -1,001.49% | -851.16% | -1,033.57% | -8,034.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 51.89M | -73.18M | -81.25M | -49.25M | -40.26M | -15.68M | -6.37M | -30.00K | -116.00K | -994.00K | -578.00K |
| Operating Income Ratio | 10.45% | -45.71% | -1,069.60% | -944.81% | -1,155.12% | -8,037.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -48.80M | -24.52M | -17.79M | -11.00M | 9.13M | 11.94M | 142.22K | -14.00K | -16.00K | 0.00 | 0.00 |
| Income Before Tax | 3.09M | -98.62M | -99.04M | -60.25M | -42.82M | -15.71M | -6.38M | -44.00K | -132.00K | -497.00K | -289.00K |
| Income Before Tax Ratio | 0.62% | -61.60% | -1,303.83% | -1,155.82% | -1,228.55% | -8,052.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.12M | 5.46M | -18.53M | -15.37M | -14.95M | -1.88M | 9.40K | -14.00K | -16.00K | -497.00K | -289.00K |
| Net Income | 5.21M | -104.08M | -80.51M | -44.89M | -27.87M | -13.83M | -6.38M | -44.00K | -132.00K | -497.00K | -289.00K |
| Net Income Ratio | 1.05% | -65.01% | -1,059.90% | -861.06% | -799.63% | -7,087.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.02 | -0.34 | -0.29 | -0.17 | -0.12 | -0.07 | -0.05 | 0.00 | 0.00 | -0.01 | -0.01 |
| EPS Diluted | 0.02 | -0.34 | -0.29 | -0.17 | -0.12 | -0.07 | -0.05 | 0.00 | 0.00 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 323.66M | 310.64M | 282.21M | 257.27M | 233.44M | 202.12M | 127.99M | 0.00 | 0.00 | 38.67M | 38.67M |
| Weighted Avg Shares Out (Dil) | 323.71M | 310.64M | 282.21M | 257.27M | 233.44M | 202.12M | 127.99M | 0.00 | 0.00 | 38.67M | 38.67M |
First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma
Telix to Present at Jefferies London Healthcare Conference 2022
A 'Game-Changing' Tool In Prostate Cancer Stokes A Huge Gain For Lantheus Stock
Telix and Merck KGaA, Darmstadt, Germany, to Commence Pan-Cancer Clinical Combination Studies
Telix Progresses Novel Lung and Ovarian Cancer Theranostic APOMAB®
Telix's TLX66 in Phase II Academic Study of Pediatric Leukemia
Kyahn Williamson Joins Telix to Lead Corporate Communications and Investor Relations
Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy
Telix Pharmaceuticals Appoints Mr. Richard Valeix as EMEA President
Source: https://incomestatements.info
Category: Stock Reports